

Thursday June 06, 2019 - I - 08:30 -10:00

Symposium 1	Symposium 02	Symposium 3	Symposium 4	Symposium 05	Symposium 06
Strategy plan to speed up access to new drugs	Pseudomonas genomics – how can we use it clinically?	From the CFTR gene to real life - <i>"Yesterday"</i>	New drugs, new identities	Cystic Fibrosis liver disease - <i>"Yellow submarine"</i>	Novel tools to better understand pathophysiology - <i>"We can work it out"</i>
Mod.: Jane Davies (UK) / Preston Campbell (US)	Mod.: Joanne Fothergill (UK) / Barbara Kahl (DE)	Mod.: Harriet Corvol (FR) / Carlo Castellani (IT)	Mod.: Pavla Hodkova (CZ) / Samantha Phillips (UK)	Mod.: Stephanie Van Biervliet (BE) / TBC	Mod.: Michael Gray (UK) / John Engelhardt (US)
Clinical trial design - Tim Lee (UK)	Global population genomics, transmission and surveillance - Craig Winstanley (UK)	The emergence of CF in the human race - Philip Farrel (US)	Managing polypharmacy: opportunities and pitfalls - Douglas McCabe (UK)	Current status on diagnosis and follow-up of Cystic Fibrosis Liver Disease - Indra van Mourik (UK)	Using Zebrafish models of inflammation to uncover new therapeutic approaches - Audrey Bernut (UK)
Ex vivo predicted modelling - Margarida Amaral (PT)	Pathogenesis, evolution and adaption to the lung - Marvin Whiteley (US)	Genetic screening in the melting pot - more data from more countries - Milan Jr Macek (CZ)	Identity and chronic illness - Anna McCulloch (UK)	Role of MRI and MRE in the diagnosis of Cystic Fibrosis Liver Disease - TBC	Using the Xenopus tadpole to study mucociliary interactions in health and CF - Eamon Dubaissi (UK)
Understanding regulatory process - Anthony Durmowicz (US)	Real time diagnostics for Pseudomonas - TBC	The impact of CFTR2 on diagnosis; an ongoing project? - Karen Raraigh (US)	New drugs and the impact on identity for people with cystic fibrosis - Ulrike Smrekar (AT)	Transient elastography in cystic fibrosis liver disease - TBC	A sheep model of CF - Ann Harris (US)
Post-approval access / challenges - Pavel Drevinek (CZ)	Making clinically relevant predictions - Rasmus Lykke Marvig (DK)	CFTR modulators for people with CFTR related disorders - the dilemma - Isabelle Durieu (FR)	I'm European, why can't I get new therapies, do I need to move country?- - Dragan Djurovic (SR)	Current and future treatment options in cystic fibrosis liver disease - TBC	Development of a 3D full thickness CF model on chip - Claudia Mazio (IT)

Thursday June 06, 2019 - II - 10:30 - 12:00

Symposium 07	Symposium 08	Symposium 09	Symposium 10	Symposium 11	Symposium 12
More adults with CF: a success but also a challenge	Orphan organs in times of CFTR modulation	The CF diagnostic all-rounder	Antimicrobial resistance in CF – are we overusing antibiotics?	Exercise and activity for young people with CF: It's not just football	CFTR, what we know and what we don't know
Mod.: Charles Haworth (UK) / Hannah Blau (IL)	Mod.: Jochen G. Mainz (DE) / Michael Wilschanski (IL)	Mod.: Nicholas Simmonds (UK) / Ana Kotnik Pirš (SI)	Mod.: Michael Tunney (UK) / Pavel Drevinek (CZ)	Mod.: Helge Hebestreit (DE) / Marlies Wagner (AT)	Mod.: Bob Ford (UK) / Sabrina Noel (FR)
Challenges of opening a new CF centre: Western European experience - Tarek Saba (UK)	Expected and unexpected gastrointestinal effects of CFTR modulation - Michael Wilschanski (IL)	Communication of diagnosis - what should be said immediately and what should be said later? - Mandy Bryon (UK)	Introduction: Defining resistance - Stuart Elborn (UK)	Which exercise and where? - Thomas Radtke (CH)	Impact of rare CFTR mutations on channel gating and stability - David Sheppard (UK)
Challenges of opening a new CF centre: Eastern European experience - Adrien Halasz (HU)	Impact of CFTR modulation on CF related diabetes - Katie Larson-Ode (US)	Is CFTR related disorder still relevant in 2019? - Carlo Castellani (IT)	Managing AMR in clinical practice-Consensus from clinicians - Anand Shah (UK)	The role of exercise as an airway clearance technique in young people with CF - Nathan Ward (AU)	Unconventional trafficking of CFTR- Min Goo Lee (KR)
Embracing technology - Gilles Rault (FR)	Effects of CFTR modulators on sino-nasal disease - Jochen G. Mainz (DE)	Functional testing of CFTR - the weaknesses and strengths of NPD and ICM - Simon Graeber (DE)	Resistance testing in selection of therapeutic antibiotics - Helle Krogh Johansen (DK)	Measuring the physiological consequence of exercise in CF - Donald Urquhart (UK)	Unravelling CFTR networks - Carlos Farinha (PT)
Infection control considerations - Charles Haworth (UK)	Are there neuromuscular and cognitive benefits from CFTR modulators? - John Wilson (AU)	Short and long-term sweat test variability - François Vermeulen (BE)	Antibiotic Stewardship – is it possible in CF? - Scott Bell (AU)	Identifying and breaking down barriers to exercise - Adam Walsh (UK)	New insights in peripheral quality control of CFTR- Tsukasa Okiyonedo (JP)
			AMR : What do our teams and patients know? - Marianne S. Muhlebach (US)		

Friday June 07, 2019 - I - 08:30 - 10:00

Symposium 13	Symposium 14	Symposium 15	Symposium 16	Symposium 17	Symposium 18
Pulmonary exacerbations	New therapies for airway disease - <i>"The long and winding road"</i>	Pre-Post lung transplant GI, liver and metabolic issues in CF	Palliative care and advanced care planning -	Interactive case studies	Cell-based therapies
Mod.: Patrick Flume (US) / Robert Gray (UK)	Mod.: Damian Downey (UK) / Silvia Gartner (ES)	Mod.: Lili Kazemi-Shirazi (AT) / Carsten Schwarz (DE)	Mod.: Nicola McDuff (UK) / Silvia Rodriguez Torres (ES)		Mod.: Nicoletta Pedemonte (IT) / Ulrich Martin (DE)
Clinical trial versus real life diagnosis of exacerbation - Ed McKone (IE)	Endpoints in airway disease- Claire Wainwright (AU)	Diabetes in the post transplant CF patient - TBC	An overview of legal challenges and opportunities of advanced care planning across Europe - Juliette Champreux (FR) / Bérénice Prieur (FR)		Human mesangioblast as an innovative cell based therapy for cystic fibrosis - Graziella Messina (IT)
Microbiome changes during exacerbation - Michael Tunney (UK)	Anti-inflammatory agents - Stuart Elborn (UK)	Bone disease before and after transplantation - Sophie Guérin (FR)	Best practice in palliative care in CF - Majda Ostir (SI)		IPS for identification of novel drugs for cystic fibrosis - Ulrich Martin (DE)
Novel biomarkers in the assessment of pulmonary exacerbations - Robert Gray (UK)	Mucoactive compounds - Felix Ratjen (CA)	GI problems post-transplant from the stomach to the colon - TBC	Moral distress as a consequence of poor advanced care planning - Kath MacDonald (UK)		Phenotypic profiling of CFTR modulators in patient-derived respiratory cystic fibrosis affected epithelia - Christine Bear (CA)
Treatment of pulmonary exacerbations in CF - Patrick Flume (US)	Anti-infectives - Giovanni Taccetti (IT)	Should we transplant just the liver, liver-lung combined or even the pancreas - TBC	Advanced care planning in the paediatric setting - Yulia Gendler (IL)		Lineage hierarchy in the airways and implication of CFTR - expressing ionocytes for cystic fibrosis disease therapy - TBC

Friday June 07, 2019 - II - 10:30 - 12:00

Symposium 19	Symposium 20	Symposium 21	Symposium 22	Symposium 23	Symposium 24
Dilemmas in CFTR modulators	Modernising microbial diagnostics	Prescribing complexities in cystic fibrosis	Micronutrition in cystic fibrosis - <i>"Strawberry fields forever"</i>	Some are more equal than others: tackling inequity in CF	Journal of Cystic Fibrosis / Lancet Respiratory Medicine - <i>"Paperback writer"</i>
Mod.: Anne Prevotat (FR) / Dorota Sands (PL)	Mod.: Debby Bogaert (UK) / Alessandra Bragonzi (IT)	Mod.: Mieke Boon (BE) / Elaine Bowman (UK)	Mod.: Anne Munck (FR) / Chris Smith (UK)	Mod: Vincent Gulmans (NL) / Nataliya Kashirskaya (RU)	Mod.: Scott Bell (AU)
Peering down the pipeline - Silke van Koningsbruggen-Rietschel (DE)	Getting the right sample - Julian Forton (UK)	The patient's perspective - Yvonne Prins (NL)	Antioxidants in CF - Oana Ciofu (DK)	The overall effect of social deprivation on people with CF - David Taylor-Robinson (UK)	
Is lung function the only player in town? - Barry Plant (IE)	Miles to go; Why Microbiome analysis is not ready yet to inform CF clinical care - Pradeep K. Singh (US)	Drug-drug interactions associated with the CFTR modulators - Martin Hug (DE)	Essential fatty acids - Birgitta Strandvik (SE)	Health literacy: what does it mean? Why is it important in CF - Abaigeal Jackson (IE)	
Will CFTR modulators reduce the burden of care? - Nicholas Simmonds (UK)	Culture is not enough. We need microbiome based diagnostics - Sébastien Boutin (DE)	Managing toxicities related to antibiotic treatment - Christopher Johnson (UK)	Sodium status and replacement in cystic fibrosis adults and children - Dimitri Declercq (BE)	Towards achieving equitable CF outcomes - Michael Schechter (US)	
CFTR modulators and adverse events - Steven M. Rowe (US)	Microbiology -The future of Registries - Alexander Elbert (US)	Management of antibiotic allergy in cystic fibrosis - Jobst Roehmel (DE)	Influence of CFTR modulation on nutritional status in cystic fibrosis - Ann Munck (FR)	Patient priorities across Europe - Jacquélien Noordhoek (NL)	

Saturday June 08, 2019 - 09:00-10:30

Symposium 25	Symposium 26	Symposium 27	Symposium 28	Symposium 29	Symposium 30
Novel clinical outcome measures in pre-school children with CF	Advances in the management of severe lung disease	Newborn Screening - where are we now?	<i>We can work it out</i> (with Registry data)	What's influencing adherence? - <i>"With a little help from my friends"</i>	Mucus; the frontline of innate defense of the lung
Mod.: Florian Singer (CH) / Margaret Rosenfeld (US)	Mod.: Michal Shteinberg (IL) / Barry Plant (IE)	Mod.: Karin M. de Winter-de Groot (NL) / Maya Desai (UK)	Mod.: Meir Mei-Zahav (IL) / Lutz Nährlich (DE)	Mod.: Bethan Phillips (UK) / Ann Raman (BE)	Mod.: Dave Thornton (UK) / Paul McNamara (UK)
Evolving parent reported outcomes - Alexandra Quittner (US)	CFTR modulator outcomes in patients with severe disease (Orkambi versus Tez-Iva experience) - Michal Shteinberg (IL)	Addressing timelines in the processing of a CF screening result - Jürg Barben (CH)	A tool to improve the accuracy of transplant referral - Thomas Daniels (UK)	Transition points in the CF journey and impact on adherence - Samantha K. Phillips (UK)	Inflammatory effects of mucus in the absence of infection - John Engelhardt (US)
Sensitive assessment of pancreatic exocrine function and response to CFTR modulators - TBC	Critical care management of the severely ill CF patient (pros and cons of NIV/intubation/ECMO) - Jens Gottlieb (DE)	The evolving situation of CFSPID/CRMS in the US - Clement Ren (US)	Comparative effectiveness research studies: a "how to" - Laura Kirwan (IE)	Socioeconomic status in chronic illness; challenging our assumptions - Klara Benesova (CZ)	Function and regulation of Muc5ac and Muc5b mucin glycopolymers - Chris Evans (US)
Does Chest MRI provide better or different information than chest CT? - Harm Tiddens (NL)	Advances in lung transplantation (donor organ optimisation/super urgent lung transplant listing etc) - Karen Redmond (IE)	CFSPID; what do physicians in Europe understand? - Silvia Gartner (ES)	Funnelling quality improvement – a casemix adjustment model for detecting centre variation - Susan C. Charman (UK)	Specific issues faced by immigrant communities - Siobhan Carr (UK)	The interaction between mucus and macrophages - Michelle Paulsen (DE)
Lung clearance index - Mirjam Stahl (DE)	Palliative care / symptom control - Helen Barker (UK)	Screening ethnically diverse populations fairly; is PAP a solution? - Olaf Sommerburg (DE)	The future of CF demography - Pierre-Régis Burgel (FR)	New technology as a means to support adherence - Georgia King (UK)	Innate lymphoid cell (ILC2) driven mucus production primes for protection at peripheral mucosal barrier sites - Laura Campbell (UK)